MedPath
HSA Approval

PACLITERO 100 SOLUTION FOR INJECTION 100MG/16.7ML

SIN16436P

PACLITERO 100 SOLUTION FOR INJECTION 100MG/16.7ML

PACLITERO 100 SOLUTION FOR INJECTION 100MG/16.7ML

March 2, 2022

HETERO SINGAPORE PTE. LTD.

HETERO SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantHETERO SINGAPORE PTE. LTD.
Licence HolderHETERO SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

INTRAVENOUS

Medical Information

L01CD01

paclitaxel

Manufacturer Information

HETERO SINGAPORE PTE. LTD.

HETERO LABS LIMITED

Active Ingredients

Paclitaxel

100mg/16.7mL

Paclitaxel

Documents

Package Inserts

Paclitero Solution for Injection_PI.pdf

Approved: March 2, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

PACLITERO 100 SOLUTION FOR INJECTION 100MG/16.7ML - HSA Approval | MedPath